

Day one

0800 Registration&Coffee 注册签到

Biopharma Industry Trends and R&D Strategy in China, Biosimilars Clinical Development

中国生物制药行业趋势与研发策略，仿制药临床开发

0830-0900

Panel Discussion: Biopharma Innovation in China: from Manufacturer to R&D Enabler

小组讨论：生物制药在中国的创新：从制造商到研发推动者

- Opportunities and Challenge in Biopharma R&D 生物药研发中的机遇与挑战
- Recent reform of the regulatory scheme for biological pharmaceutical products 近期生物药产品监管方案的改革
- Accelerate the entry of biological drugs into therapeutic 加快生物药进入治疗领域
- Discussion on the key points in the process of biological drug evaluation 生物药审评过程中的关节点探讨
- How can Chinese biopharma leverage global resources to power its innovation? 中国生物制药如何利用全球资源推动创新
- Partnership models and roles of major players in China--CRO,CMO, domestic Biotech/Pharma, international Biotech/Pharma, academics and government 中国生物药主要参与者之间的合作模式与角色定位---国内生物技术/制药、国际生物技术/制药、CRO、CMO, 学术界和政府等

Moderator:

Jing He, Head of global drug development center (China), Roche Pharmaceutical 罗氏药业

Panelist:

Sam Guhan, Vice President, Drug Product Technologies, Process Development, Amgen, USA 安进制药, 美国

Huijun Gao, Senior Engineer, Secretary General, Shanghai Association of Food and Drug Safety 上海食品药品安全研究会

Qiang Lv, Co-founder, Pumishi Biotech 普米斯生物

Zhenping Zhu, President of R&D and SCO, 3SBio Inc, China 三生国健

Ruilin Song, Executive President, PhIRDA 中国医药创新促进会

Quanhong Yuan, Partner, CCB Capital 苑全红, 合伙人, 建信资本

Dawei Li, Professor, Principal Investigator, Shanghai Jiaotong University, School of Pharmacy, Engineering Research Centre of Cell and Therapeutic Antibody, Ministry of Education 上海交通大学药学院细胞和治疗性抗体工程研究中心

0900-0930

A New Model of Innovative Biologics Drug R&D

创新生物药物研发的新模式

Zhihong Lu, VP of Research & Development, Simcere Pharmaceutical Group 先声药业

0930-1000

Looking to the future - Innovative technologies to Promote drug development

展望未来---创新技术推进药物开发

Yuan-Hua Ding, Executive Director and Head of Pfizer External Science & Innovation (ES&I) – Asia/Pacific, Pfizer Worldwide Research & Development 丁元华, 亚太区外部科学与创新执行总监兼负责人, 辉瑞研发

1000-1030

Pharmaceutical and clinical development strategies of biosimilar drugs in China

国内生物类似药的药学和临床开发策略

Haibin Wang, Senior Vice President, Zhejiang Hisun Pharmaceutical 浙江海正药业股份有限公司

1030-1100

Tea and Coffee Break 茶歇

1100-1130

Panel Discussion: Growing Biotech 生物技术发展讨论

Moderator:

Hongbo Lu, Partner, Lilly Asia Ventures 礼来亚洲基金

Panelist:

Claudia Lin, CEO, JADE BioMedical 驾玉生物医药有限公司

Jinzi Wu, President & CEO, Ascletris 歌礼生物科技

Li Jiangqing, Founder & CSO, HeBei Senlang Biotechnology Inc. Ltd, China 河北森朗生物

Hongtao Lu, Co-Founder and CSO, Elpiscience Biopharma 科望生物医药

Hui Shao, President & CEO, Liaoning Yisheng Bio 辽宁依生生物

Hui Feng, COO, Junshi Bio 骏实生物科技(上海)有限公司

1130-1200

Solution Provider Session 技术与解决方案提供商:

1200-1230

The experience in the R&D of first Biosimilar Drugs

第一个生物类似药的研发经验

Scott Liu, CEO, Shanghai Helius Biotech 上海复宏汉霖生物技术

1230 Networking & Luncheon 午宴与交流时间

**Bispecific and Novel Antibody Development, Design and Engineering
Improvement of Bispecific Antibodies and ADCs for druggability
双特异性和创新抗体开发, 围绕成药性的双/多抗设计与工程改进**

1330-1400

Innovative antibody drug development for autoimmune diseases

针对自身免疫性疾病的创新抗体药物开发

Yu Xia,CEO,Akeso Bio 中山康方生物医药有限公司

1400-1430

PD-1/PD-L1's Clinical application of antibody and the latest clinical research progress

PD-1/PD-L1 抗体临床应用及最新临床研究进展

Lianshan Zhang,President of R&D,Jiangsu Hengrui Pharmaceutical 江苏恒瑞医药股份有限公司

1430-1500

Solution Provider Session 技术与解决方案提供商:

1500-1530

Clinical research progress of CAR-T combined therapy for malignant solid tumors

恶性实体肿瘤 CAR-T 联合治疗临床研究进展

Qing Xu, Dean, Tongji cancer center, The 10th people's hospital of Shanghai 上海十院同济癌症中心

1530-1600

Tea and Coffee Break 茶歇

1600-1630

Innovative research and development of anti-infective Antibody drugs

抗感染类抗体药物的创新研发

Lichun Wang, CEO, PUREmAb Biotech 上海普铭生物科技有限公司

1630-1700

A Tetravalent Bispecific Antibody with Strong Activity in Inducing Target Degradation and

Tumor Regression 一种四价双特异性抗体，具有很强的诱导靶细胞降解和肿瘤消退的活性

Chenbing Wu, CEO, Epimab Biotech 上海岸迈生物科技有限公司

1700-1730

Improving clinical trials with better stakeholder management

通过更好的利益相关者管理提升临床试验

Yongho Oh, Regional Clinical Project Manager & ISS Project Manager, JPAC and China, Sanofi 赛诺菲

1730-1800

The next big trend in Asia immunotherapy landscape: A case study in China

亚洲免疫治疗领域的下一个大趋势:在中国的一个案例

Frank Jiang, CEO, Cstone pharmaceuticals 基石药业

1800-1830

Sharing of innovative biological drugs on Preclinical and clinical bioanalysis strategies and case study

生物类创新药的临床前和临床生物分析策略及案例分享

Jing Shi, Senior Director of Bioanalysis,Wuxi Apptec 上海药明康德新药开发有限公司

Day Two

0800 Registration&Coffee 注册签到

Cell Culture and Cell Line Development , Upstream Processing, Downstream Processing, Integrated and Continuous Processing 细胞培养和细胞系开发, 上下游工艺流程, 一体化及连续工艺

0830-0900

Panel Discussion :Next Generation Bioprocessing, Digitalization and Facilities of the Future

小组讨论: 下一代工艺开发, 数字化和未来厂房建设

Moderator:

Weichang Zhou, Senior Vice President, Biologics Development and Manufacturing, WuXi Biologics 无锡生物

Panelist:

Uwe Voelker, Site Head, Sterile Drug Product Manufacturing, Roche, Germany 罗氏医药, 德国

Garry Takle, Associate Vice President, Biologics and Vaccines Analytics, Merck & Co., USA 默克

Marcus Fiadeiro, Associate Director, DSP Continuous Manufacturing, Sanofi 赛诺菲

Junli Zhang, Senior Vice President of Global Manufacturing and Technical Operation, Shanghai Henlius Biotech, Inc. 上海复宏汉霖生物技术

Jiajian Liu, Founder and CEO ,L&L Biopharma, Co. LTD 健信生物医药

Grace Yeh, President & CEO, PharmaEngine 智擎生技制药

0900-0930

CRISPR in Cell Line Development: Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines

CRISPR 在细胞系开发的应用:CRISPR 在稳定转基因 CHO 细胞系快速开发中的应用

Jianwei Zhu, Chair Professor and Dean of School of Pharmacy, Shanghai Jiao Tong University (SJTU) 上海交通大学; Director of MOE Engineering Research Center of Cell Engineering and Antibody; President and Chief Executive Officer, Jecho Biopharmaceuticals, China 杰科(天津)生物医药有限公司

0930-1000

Implementation of Continuous Manufacturing Facility to Increase Flexibility and Capacity – A Case Study of an Antibody Continuous Process Scale-up

持续性生产厂房的使用提升灵活性和容量---单抗持续性工业放大的案例分析

Xiaoming Yang, SVP, Product and Process Development, GM, CDMO Business Unit, Hangzhou Just Biotherapeutics Ltd. 杭州奕安济世生物药业有限公司

1000-1030

Solution Provider Session 技术与解决方案提供商:

1030-1100

Tea and Coffee Break 茶歇

1100-1130

Cell Culture and Purification Process Development Strategy from Analytical Approach

通过分析方法来查看细胞培养和纯化工艺开发策略

Eric Chang, Head of Cell Line Development, JHL Biotech, Taiwan 喜康生物

1130-1200

Innovative Strategies for Enhancing HCP Clearance in Clarification and Downstream Processing

在净化和下游工艺开发中提高 HCP 清除率的创新策略

Benoit Mothes, Head of Global DSP Breakthrough Technologies Skill Center, Sanofi 赛诺菲

1200-1230

Fast-Tracking Clone Selection and CLD Optimisation Workflows / Evolving Transfection and Continuous Expression Systems

快速跟踪克隆选择和 CLD 优化工作流程/进化转染和连续表达系统

Minmin Qin, Senior Vice President and Head, CMC, Harbour BioMed, China 和铂医药

1230Networking & Luncheon 午宴与交流时间

Technology Transfer and Biomanufacturing Strategies; Analytical Characterization, Quality Control and Single Use Systems

技术转让和生物制造策略：分析特异性，质量控制，一次性系统

1330-1400

Spotlight Presentation in Characterisation, Small-Scale Analysis, Stable Cell Lines, Quality, Titre 在特异性，小规模分析，稳定的细胞株，质量，滴度的聚焦展示

James (Jianguo) Yang, Chief Executive Officer, Tayu Huaxia Biotech Medical Group, China 大有华夏生物医药集团

1400-1430

Smart Bioprocessing and Manufacturing Use Case in China

中国智能生产工艺和生产使用案例分享

WeiChun Wang, Vice President of Biologics Process Development, WuXi Biologics, China 无锡生物

1430-1500

Solution Provider Session 技术与解决方案提供商:

1500-1530

Large Scale Manufacturing and Quality by Design

通过设计把控大规模生产和质量

Wu Youling, Chief Executive Officer, ZheJiang Teruisi Biopharmaceutical, China 浙江特瑞思生物医药

1530-1600

Tea and Coffee Break 茶歇

1600-1630

Implementation of BPOG's Biomanufacturing Technology Roadmap: Progress, Challenges and Prospects

BPOG 生物制造技术路线图的实施:进展、挑战和前景

Akihiro Yanagita, Group Manager of Bio Purification Process Development, Chugai Pharmaceutical Company Ltd. 日本中外制药株式会社

1630-1700

Case Studies in Cell and Gene Therapy Production

细胞和基因治疗生产案例分析

Lin Yang, Chief Executive Officer, PersonGen Biomedicine, China 博生吉生物医药科技(苏州)

1700-1730

Installation Strategies of Single-Use Technologies for Downstream Processing

一次性技术在下游工业开发的安装策略

Kosuke Takenaka, Principal Scientist, Pharmaceutical Science, Biopharmaceutical Process and Product Development, Takeda Pharmaceutical Company Limited 武田制药

1730-1800

Challenges & Opportunities in Process Transfer and Process Control

工艺转让和控制的挑战和机遇

Xu Wei, Vice President, Manufacturing, Innovent Biologics, China 信达药业

1800-1830

iLDC Based Continuous Process, Future Direction on CMC of Next Generation ADCs

基于 iLDC 的连续工艺, 基于 CMC 的下一代 ADCs 未来发展方向

Gang Qin, President, GeneQuantum Healthcare (Suzhou) Co., Ltd. 启德医药科技(苏州)

1830 Conference Adjourn 大会结束

备注: 日程内容/时间安排以会议当天公布为主, 主办方将保留解释权